Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolinium-Based Contrast Agent: A Systematic Review and Meta-analysis ca. 2019
#VisualAbstract by @VickiSandys1
#NephJC #Nephpearls
👉🏼 jamanetwork.com/journals/jamai…
Chart showing cumulative Nephrogenic Systemic Fibrosis (NSF) cases reported to the NSF Registry by date of onset through 2012
📌 Important FDA announcements are marked on the timeline
#Nephpearls #NephJC
Depiction of the current gadolinium-based contrast agents approved for clinical use in Canada 🇨🇦 #Nephpearls #NephJC
👉🏼 ncbi.nlm.nih.gov/pmc/articles/P…
Which is WORSE ⁉️ Risk of Gadolinium Nephrotoxicity or Radiocontrast Nephropathy #Nephpearls #NephJC #AskRenal
On GADOLINIUM and the Kidney
1⃣ Nephrogenic Systemic Fibrosis
2⃣ AKI
3⃣ Pseudohypocalcemia
#Nephpearls #NephJC
👉🏼 ncbi.nlm.nih.gov/m/pubmed/18033…
In this illustration, a nonionic linear chelate (gadodiamide), which binds Gd3 less tightly than other chelates (macrocyclic and ionic), is shown undergoing the process of transmetallation #Nephpearls #NephJC
👉🏼 cjasn.asnjournals.org/content/clinja…
Nephrogenic Systemic Fibrosis: Differential Diagnosis #Nephpearls #NephJC
👉🏼 mdedge.com/ccjm/article/9…
Nephrogenic Systemic Fibrosis: Prevention and Treatment from @NephRodby’s lecture
#NKFClinicals 2019 #Nephpearls #NephJC
👉🏼 ncbi.nlm.nih.gov/m/pubmed/17555…
Although Nephrogenic Systemic Fibrosis occurrence after exposure to newer GBCAs is very rare, the relatively scarce data among patients w/ AKI and those w/ risk factors for CKD limit conclusions about safety‼️ (ca. 2020) from @AnnalsofIM #Nephpearls
👉🏼 acpjournals.org/doi/pdf/10.732…
Risks and Options With Gadolinium-Based Contrast Agents in Patients With CKD: A Review ca. 2020 from @AJKDonline @MichaelRudnick7 #Nephpearls
👉🏼 ajkd.org/action/showPdf…
Share this Scrolly Tale with your friends.
A Scrolly Tale is a new way to read Twitter threads with a more visually immersive experience.
Discover more beautiful Scrolly Tales like this.